Scarica l'app Stockscreener
2.22
3.48%
-0.08
Dopo l'orario di chiusura:
2.26
0.04
+1.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$2.30
Aprire:
$2.27
Volume 24 ore:
2.16M
Relative Volume:
0.87
Capitalizzazione di mercato:
$369.56M
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-0.7929
EPS:
-2.8
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
-3.06%
1M Prestazione:
-32.11%
6M Prestazione:
-66.26%
1 anno Prestazione:
-67.83%
Intervallo 1D:
$2.065
$2.295
Intervallo di 1 settimana:
$1.775
$2.37
Portata 52W:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
399 BINNEY STREET, CAMBRIDGE
Confronta RLAY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
2.22 | 369.56M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.87B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 61.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.66B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.70B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
Norges Bank Takes $23.82 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Raymond James Financial Inc. Invests $779,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Cancer drug developer cuts staff for the third time in a year - The Business Journals
Relay Therapeutics Inc (RLAY) Recovers -2.97% From Low: Are We There Yet? - stocksregister.com
Thrivent Financial for Lutherans Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Teacher Retirement System of Texas Purchases 5,492 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics stock hits 52-week low at $2.44 - Investing.com India
Relay Therapeutics stock hits 52-week low at $2.44 By Investing.com - Investing.com UK
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Virtu Financial LLC - Defense World
Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook - Investing.com
Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! - Insider Monkey
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges - Investing.com India
Bank of New York Mellon Corp Buys 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Investor Alert: What’s Really Going On At Relay Therapeutics Inc (NASDAQ: RLAY) - Stocks Register
Victory Capital Management Inc. Has $63,000 Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Steward Partners Investment Advisory LLC Purchases 4,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Head-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition - Investing.com India
Arizona State Retirement System Acquires 7,547 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
HC Wainwright Reiterates “Buy” Rating for Relay Therapeutics (NASDAQ:RLAY) - Defense World
Rhumbline Advisers Acquires 13,532 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
New York State Common Retirement Fund Has $121,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - Defense World
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low After Analyst Downgrade - Defense World
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP - TipRanks
Relay Therapeutics stock target cut to $12 at Citizens JMP - Investing.com
Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments - TipRanks
RLAY stock touches 52-week low at $3.34 amid market challenges - Investing.com
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relay Therapeutics Inc Azioni (RLAY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Mar 27 '25 |
Sale |
2.84 |
247 |
701 |
402,184 |
| Catinazzo Thomas | Chief Financial Officer |
Mar 27 '25 |
Sale |
2.84 |
4,864 |
13,814 |
374,567 |
| Adams Brian | Chief Legal Officer |
Mar 27 '25 |
Sale |
2.84 |
298 |
846 |
405,972 |
4.35%
10.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):